Companies › Kanyos Bio

Kanyos Bio

Healthcare 📍 Cambridge, United States 👥 1001-5000 employees 💰 $16.4M raised 📅 Founded 2015

Kanyos Bio was founded with the goal of developing antigen-specific immune tolerance technology for two specific autoimmune indications, type-1 diabetes and celiac disease. Our technology originated at EPFL (Ecole Polytechnique Fédérale Lausanne) in Switzerland with our sister company, Anokion. Kanyos and Anokion are

📊 Company Overview

Sector
Healthcare
Country
United States
Employees
1001-5000
Total Raised · Venture
$16.4M
Founded
2015
Cloud
Unknown

☁️ Cloud Infrastructure

🔒 Subscribers only Cloud Provider
Workspace🔒 Subscribers only
CDN🔒 Subscribers only

Detected via DNS records and HTTP response headers as of 2026-06-13.

💰 Estimated Cloud Spend

$11M $27M / year across cloud providers

🛠 Tech Stack & Marketing

Ad Platforms🔒 Subscribers only
Analytics & CRM🔒 Subscribers only
CMS / Platform🔒 Subscribers only
Frontend Stack🔒 Subscribers only

Detected from Kanyos Bio's public homepage as of 2026-06-13.

🔍 Compare with Similar Companies

Same sector (Healthcare), similar size

Data detected 2026-06-13 · Methodology · Suggest a correction